Viking Therapeutics Secures $350M to Accelerate Breakthrough Therapies in Metabolic and Endocrine Disorders

Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company at the forefront of developing first-in-class or best-in-class therapies for metabolic and endocrine disorders, is proud to announce a funding milestone of $350 million. This significant capital infusion marks a pivotal moment for the company as it continues to forge ahead in its mission to address critical unmet medical needs. Viking Therapeutics is leveraging this new financial backing to further advance its cutting-edge drug candidates through clinical development and to potentially transform the lives of patients suffering from a host of serious conditions. The company’s leading candidate—a non-steroidal selective androgen receptor modulator (SARM) currently in Phase 2 trials—targets recovery from hip fracture surgery, aiming to enhance the rehabilitation process and improve outcomes for a vulnerable patient population. In addition, the recently raised funds will accelerate the development of Viking’s thyroid receptor beta (TRb) agonist platform, a promising therapeutic approach in Phase 2 studies. This platform is not only being investigated for lipid disorders, including hypercholesterolemia, but also for fatty liver diseases such as non-alcoholic steatohepatitis (NASH) as well as rare metabolic diseases like glycogen storage disease type 1a (GSD 1a) and X-linked adrenoleukodystrophy (X-ALD). With this robust financial support, Viking Therapeutics is well-positioned to expand its research and clinical pipeline, enhance its operational capabilities, and ultimately deliver innovative treatment options to patients suffering from complex metabolic and endocrine conditions. This funding announcement solidifies the company’s commitment to scientific excellence and its dedication to providing hope where it is most needed. For more details about the company and its groundbreaking work, please visit http://www.vikingtherapeutics.com.